# Apixaban During Atrial Fibrillation Catheter Ablation: Comparison to Vitamin K Antagonist Therapy

Study · id `cardio:ct-nct02227550` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02227550](<https://clinicaltrials.gov/study/NCT02227550>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02227550

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 676 participants.

## Technical summary

Registry record NCT02227550. Randomized; no masking; primary purpose treatment. Start 2014-12 (registry gives no type); primary completion 2017-04 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 676 participants (enrolled count; ClinicalTrials.gov record NCT02227550, source copy `cardio:ctgov-nct02227550-2017-10-20`, retrieved 2026-10-26)
- Start date: 2014-12 (registry gives no type) (ClinicalTrials.gov record NCT02227550, source copy `cardio:ctgov-nct02227550-2017-10-20`, retrieved 2026-10-26)
- Primary completion: 2017-04 (actual) (ClinicalTrials.gov record NCT02227550, source copy `cardio:ctgov-nct02227550-2017-10-20`, retrieved 2026-10-26)
- Completion: 2017-09 (actual) (ClinicalTrials.gov record NCT02227550, source copy `cardio:ctgov-nct02227550-2017-10-20`, retrieved 2026-10-26)
- Countries: United States; Austria; Belgium; Denmark; Germany; Italy; Netherlands; Spain; United Kingdom (ClinicalTrials.gov record NCT02227550, source copy `cardio:ctgov-nct02227550-2017-10-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02227550-2017-10-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: Apixaban During Atrial Fibrillation Catheter Ablation: Comparison to Vitamin K Antagonist Therapy
- Acronym: AXAFA
- Condition: Atrial Fibrillation
- Intervention (Drug): Vitamin K antagonist
- Intervention (Drug): Apixaban
- Lead sponsor: Atrial Fibrillation Network
- Lead sponsor class: OTHER
- Collaborator: Bristol-Myers Squibb
- Collaborator class: INDUSTRY
- Collaborator: Pfizer
- Collaborator class: INDUSTRY
- Collaborator: Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry intervention name matches this record: Apixaban (`cardio:apixaban`)
- Registry lists this organization as the lead sponsor: Atrial Fibrillation Network (`cardio:org-atrial-fibrillation-network`)
- Registry lists this organization as a collaborator: Bristol-Myers Squibb (`cardio:org-bristol-myers-squibb`)
- Registry lists this organization as a collaborator: Pfizer (`cardio:org-pfizer`)
- Registry lists this organization as a collaborator: Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK) (`cardio:org-deutsches-zentrum-fur-herz-kreislauf-forschung-dzhk`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: MRI-Detected Brain Lesions and Cognitive Function in Patients With Atrial Fibrillation Undergoing Left Atrial Catheter Ablation in the Randomized AXAFA-AFNET 5 Trial (`cardio:pubmed-35135308`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 1bfe02e38be512763bb0ddc965305df2ebd09ed36a03e4bc9572848719da4869
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
